ROBERTA LATTANZI

Curriculum Vitae

Roberta Lattanzi
Via Francesco Bonfiglio 43, 00168 Rome, Italy
Phone: +39-06-49912501 | E-mail: Roberta.Lattanzi@uniroma1.it

Current Position
Associate Professor of Pharmacology (SSD: 05/BIOS-11/A)
Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Italy
National Scientific Qualification

• National Scientific Qualification for Full Professor, Session 2021–2023
Field: Pharmacology, Clinical Pharmacology, and Pharmacognosy (05/G; SSD: 05/BIOS- 11/A) Awarded: September 9, 2023

Education
PhD in Cellular and Molecular Pharmacology
Institute of Medical Pharmacology, Sapienza University of Rome, Italy, November 1996 • Thesis: “[Lys7]dermorphin, a Highly Selective Opioid Peptide for μ Receptors” MSc in Biological Sciences
Faculty of Mathematical, Physical and Natural Sciences, Sapienza University of Rome, Italy, May 1992 • Thesis: “Ontogenesis of δ Opioid Receptors in the Mouse Brain”

Research Experience and Responsibilities
• Principal Investigator of a Pharmacology laboratory focused on neuropeptides
• Conducting research on the molecular and cellular mechanisms of opioid and other neuropeptide systems
• Research output (Scopus, September 2024):
o Publications: 107
o h-index: 29
o Total citations: 2.656

My research has focused on the functional role of neuropeptides, investigating their involvement in various biological activities, particularly in the modulation of nociceptive transmission.
For several years, using receptor binding techniques and in vitro and in vivo pharmacological activity assays, I contributed to studies on dermorphins and deltorphins, two important classes of opioid peptides.
More recently, I have participated in the identification of a new protein system (Bv8/prokineticins) and their receptors, contributing to the study of the multiple physiological and pathological activities in which this system is involved. In particular, I have focused on elucidating the molecular and cellular mechanisms underlying prokineticin-induced nociceptive sensitization and on studying the involvement of the prokineticin system in conditions of inflammation and neuroinflammation

Funded Research Projects As Principal Investigator (PI)
• 2025: Pasteur Institute Italy, Cenci Bolognetti Foundation Grant – The Prokineticin System as a Link Between Alzheimer’s Disease and Dysbiosis. 40000 €. March 2025- February 2027
• 2023: Research grant from Dompé S.p.A. in collaboration with Prof. Alessandro Lambiase, Department of Sense Organs, Sapienza University of Rome. Effect of prokineticin receptor antagonists on angiogenesis in ocular diseases. 15000 €. 2023- 2026
• 2022: SEED PNR Project – A New Potential Neuroinflammatory Biomarker in Alzheimer’s Disease (AD): Analysis of Prokineticin 2 Serum Levels in AD Patients at Different Stages
• 2019: University Research Project – Role of PK2/PKRs in Chronic Pain Induction and Maintenance: New Pharmacological Strategies to Control Pain and Neuroinflammation, Protocol: RM11916B73F9245A
• 2018: University Research Project – The Prokineticin System: A Potential New Therapeutic Target for the Pharmacological Treatment of Depression, Protocol: RM1181643677A1D0
• 2017: FABR (Funding for Basic Research Activities)
• 2016: University Project – Involvement of the Prokineticin System in Brain Pathological States: Amyloid-β-Induced Neurotoxicity, Protocol: RM116154C973F8
• 2015: University Project – Involvement of the Prokineticin System in Brain Pathological States: Amyloid-β-Induced Neurotoxicity, Protocol: C26A152LL.L
• 2009: PRIN (Scientific Research Projects of National Relevance) – Role of a New Family of Chemokines – Prokineticins – in Neuropathic Pain, Protocol: 20099F3XPM-003
• 2009: Federated University Research in Public and Health Policy Sciences (SPPS) – Role of Bv8 in the Regulation of Water Balance in the Rat, Protocol: C26F09JANK
• 2008: Federated University Research in Public and Health Policy Sciences (SPPS) – Pharmacological Characterization of New Anti-Hyperalgesic Molecules, Protocol: C26F08ZPTH
• 2007: Federated University Research in Public and Health Policy Sciences (SPPS) – Pharmacological Characterization of New Ligands for Opioid Receptors, Protocol: C26F07HANZ
• 2001: MURST – Young Researchers Project – Bv8, a New Dipogenic Peptide
• 2000: Funded by the National Research Council (CNR) – Young Researchers Program, Local Cerebral Glucose Consumption and Behavioral Effects Induced by Opioid Peptides in Rats, Protocol: CNRG00147E

As Project Participant
• 2023: University Research Project – Dissecting the Mechanisms Underlying the Impact of Maternal Environmental Risk Factors on Offspring Mental Health, Protocol: RM123188F2BB5F57
• 2022: University Research Project – Investigating the Role of Astrocytes in Oligodendrocyte Maturation and Myelin Formation in Cellular Models of Alzheimer’s Disease: A Preclinical Study with Co-Ultramicronized Palmitoylethanolamide/Luteolin, Protocol: RG12218168987A63
• 2020: University Research Project – A Network Approach to Understand the Neurobiology of the Distributed Practice Effect, Protocol: RG120172B798BF17
• 2014: University Research Project – Maternal Exposure to Low Levels of Corticosterone During Lactation in Rats: Effects on Susceptibility to the Development of Inflammatory Colitis in Adult Offspring of Both Sexes, Protocol: C26A14JXCR
• 2011: University Research Project – Structural and Functional Characterization of Bioactive Peptides and Their Role in Immune Processes, Protocol: C26A11HHB5
• 2010: University Research Project – Structural Adaptation of Type I Pyridoxal-5'-Phosphate- Dependent Enzymes to Extreme Environmental Conditions, Protocol: C26A10JY5S
• 2004: PRIN (Scientific Research Programs of National Relevance) – Molecular Mechanisms and Structural Determinants Responsible for Nociceptive Sensitization Induced by Bv8-Prokineticin Proteins, Protocol: 2002034574-006
• 2002: PRIN (Scientific Research Programs of National Relevance) – Analgesic Potency and CNS Bioavailability of Modified Analogues of Natural Opioid Peptides, Protocol: 2002034574-006

Third Mission / Public Engagement
• 2024: Breathe Sapienza! Sciences in synergy and an active community against the epidemic of vaping and tobacco smoking, for the protection of public health, environmental sustainability, and future well-being." Number protocol:TM124192E29DB113
• 2023: Deciphering Contemporary Times: Collaborative Models for a Critical Understanding of Present-Day Complexity . Number protocol: TM12318B85AA0565
• 2022: For a Necessary Theatre: University, Prison, and School – An Inclusive Model of Public Engagement and Integrated Education Through Theatre.
Awards and Recognitions
• 2017. FABR Funding (Basic Research Activities Funding). Competitive funding aimed at supporting basic research carried out by researchers and associate professors employed full-time at state universities. January 1, 2017 – December 30, 2017
• 1999. Funding from the Organizing Committee of the International Narcotics Research Conference (INRC) for participation in the 30th International Narcotics Research Conference, Saratoga Springs, New York, U.S.A., July 10–15, 1999.
• 1999: Funded by the Board of Directors of the Italian Society of Pharmacology (SIF) for participation in the XXIX Congress of the Italian Society of Pharmacology, Florence, Italy, June 20– 23, 1999
• 1999: Funded by the Board of Directors of the Italian Society of Pharmacology (SIF) for participation in the Joint Meeting of the French and Italian Societies of Pharmacology, Nantes, France, March 15–17, 1999
• 1998: Funded by the Organizing Committee of the International Narcotics Research Conference (INRC) for participation in the 29th International Narcotics Research Conference, Garmisch- Partenkirchen, Germany, July 20–25, 1998
• 1998: Funded by the Board of Directors of the Italian Society of Pharmacology (SIF) for participation in the 6th Joint Meeting of the Italian, Hungarian, and Polish Pharmacological Societies, Pisa, Italy, May 14–16, 1998.
• 1997. Funding provided by the Italian Society of Pharmacology (SIF) to support the stay of young researchers abroad. Specifically, to fund an Accademia dei Lincei – Royal Society Exchange Fellowship for conducting research titled: "Study of the Expression and Localization of Opioid Receptors in the Central Nervous System of Transgenic Mice Using Autoradiographic Techniques" Department of Neuropharmacology, School of Biological Sciences, University of Surrey, Guildford, U.K. September 20, 1997 – December 30, 1997
• 1997: Funded by the Board of Directors of the Italian Society of Pharmacology (SIF) for participation in the XXVIII National Congress of the Italian Society of Pharmacology, Bari, Italy, April 30–May 3, 1997
• 1996: Funded by the Organizing Committee of the International Narcotics Research Conference (INRC) for participation in the 28th International Narcotics Research Conference, Long Beach, California, USA, July 21–26, 1996

Speaker at the following conferences:
• XXVIII National Congress of the Italian Society of Pharmacology. Bari, April 30 – May 3, 1997. Presentation title: “Respiratory responses after s.c. injection of the μ-opioid agonist [Lys7]dermorphin in rats”, published in Pharmacological Research, vol. 35 supplement, p. 89.
• 6th Joint Meeting of the Italian, Hungarian, and Polish Pharmacological Societies. Pisa, May 14–16, 1998. Presentation title: “HS-599: a novel opioid analgesic with agonist-antagonist activity”.
• VI Joint Meeting of the British and Italian Pharmacological Societies. Birmingham, December 18–21, 2000. Presentation title: “Pharmacology of BV8: a new peptide from amphibian skin”, published in Br. J. Pharmacol., vol. 133 proceedings supplement, 45P.
• XXXII National Congress of the Italian Society of Pharmacology. Naples, June 1–4, 2005. Presentation title: “Impaired nociception in mice lacking the receptor 1 of Bv8/prokineticins (PKR1)”.
• XXXIII National Congress of the Italian Society of Pharmacology. Cagliari, June 6–9, 2007. Presentation title: “Prokineticins participate in development of inflammatory pain”.
• XXXIII National Congress of the Italian Society of Pharmacology. Cagliari, June 6–9, 2007. Presentation title: “Prostanoid system is involved in Bv8-induced nociception”.
• XXXIV National Congress of the Italian Society of Pharmacology. Rimini, October 14–17, 2009. Presentation title: “Targeting Bv8/prokineticin receptors in inflammatory pain”.
• XXXV National Congress of the Italian Society of Pharmacology. Bologna, September 14–17, 2011. Presentation title: “Bv8/prokineticin receptor antagonists: novel antihyperalgesic and anti- inflammatory drugs”.
• XV Congress of the Italian Society of Neuroscience (S.I.N.S.). Rome, October 3–5, 2013. Presentation title: “A new player in neuropathic pain: the Bv8/Prokineticin System”.
• XXXVII National Congress of the Italian Society of Pharmacology “The new horizons of pharmacological research: between ethics and science”. Naples, October 27–30, 2015. Presentation title: “Bv8/Prokineticin2 in pain transmission” within the symposium titled “TRP channels and other targets”.

Invited Speaker at the following conferences:
• Cellular and Molecular Aspects of Pharmacologic Control of Pain Parghelia (VV), Italy, September 23th, 2010 Talk title: “New Non-Peptide Antagonists of the Prokineticin Receptors”
• New Trends in Pain Research: From Basic Research to Clinical Translation Parghelia (VV), Italy, September 13th–15th, 2012 Talk title: “New Trends in Prokineticin Research”
• International Narcotic Research Conference (INRC) 2025. Satellite Meeting, University of Calabria, Rende (Cosenza), Italy, July 6th-8th, 2024 Talk title: “Prokineticin in Chronic Pain”
• First Meeting of the italian GPCR Network. Bari, Italy, February 14 th. Talk Title: Prokineticins and prokineticin receptors are involved in inflammation and neuroinflammation

Teaching Experience Master’s Degree Programs
• 2007–present: Lecturer in Pharmacology and Toxicology, Bachelor of Medicine and Surgery (Course B), Sapienza University of Rome, Rome – Course Coordinator
• 2019–present: Lecturer in Pharmacology, Dentistry and Dental Prosthetics, Sapienza University of Rome, Rome
• 2007–2010: Lecturer in Pharmacology and Toxicology, Bachelor of Medicine and Surgery (Course E), Sapienza University of Rome, Latina
• 2015–2023: Chair of the Pharmacology Examination Committee (F.C., Table XVIII ‘96), Sapienza University of Rome, Rome
• 2017–2019: Lecturer in Pharmacology and Toxicology, Bachelor of Medicine and Surgery (Course D), Sapienza University of Rome, Rome

Bachelor’s Degree Programs
• 2021–present: Lecturer in Pharmacology and Toxicology, Bachelor of Biology, Sapienza University of Rome, Rome
• 2002–2013: Lecturer, Pharmacology Module (Integrated Course in Critical and Emergency Nursing), Bachelor of Nursing Sciences (Course G), Sapienza University of Rome, Colleferro
• 2002–2017: Lecturer, Pharmacology Module (Clinical Nursing in Medical Area), Bachelor of

Nursing Sciences (Course G), Sapienza University of Rome, Colleferro
o 2012–2017: Course Coordinator, Clinical Nursing in Medical Area
• 2015–2023: Lecturer, Pharmacology Module (Courses in ENT Sciences and Preventive Audiology), Bachelor of Audiometric Techniques, Sapienza University of Rome, Rome
• 2016–2018: Lecturer, Pharmacology Module (Clinical Nursing in Medical Area), Bachelor of Nursing Sciences (Course C), Sapienza University of Rome, Rome
o 2017: Course Coordinator
• 2016–2021: Lecturer, Pharmacology Module (Clinical Nursing in Medical Area), Bachelor of Nursing Sciences (Course E), Sapienza University of Rome, Santo Spirito, Rome
• 2009–2017: Lecturer, Pharmacology Module (Clinical Nursing in Medical Area), Bachelor of Nursing Sciences (Course N), Sapienza University of Rome, Bracciano
o 2012–2017: Course Coordinator, Clinical Nursing in Medical Area

Master’s Programs
• 2021–2023, 2025: Lecturer, Master in Integrated Medicine in Pharmacy, Sapienza University of Rome
o Courses: Pharmacology of Diabetes, Pharmacological Therapy of Hypertension, Pharmacological Therapy of Dyslipidemia, Pharmacological Treatment of Acute and Chronic Pain
• 2006: Lecturer, Master Biological Rhythms in Diagnostics and Clinical Practice, Sapienza University of Rome
o Lecture: Biological Rhythms in Pharmacology PhD Supervision and Teaching
• Member of the Doctoral Board, PhD in Pharmacology and Toxicology, Sapienza University of Rome (2008–2014, 2016–present)
• Supervision of PhD students in Pharmacology and Toxicology
• Courses for PhD students:
o Pharmacology of Pain (2017, 2018, 2023, 2024)
o Receptor Binding Techniques (2014)
• Member of PhD examination committees (admission and final exams) at Sapienza University of Rome and University of Milan.
• Supervision of undergraduate experimental and review theses, and participation in thesis defense
committees for Medicine and Surgery, Biological Sciences, and Nursing Sciences as thesis advisor

Academic Activities
• July 2022: Appointed Member of the University Research Committee, Sapienza University of Rome Book Chapters
• Negri, L., Lattanzi, R. (2015). Neuropeptides. In: F. Clementi & G. Fumagalli, General and Molecular Pharmacology. UTET, Turin
• Negri, L., Melchiorri, P., Lattanzi, R. (2013). Opioid and Bv8 Peptides. In: A.J. Kastin (Ed.), Handbook of Biologically Active Peptides
• Negri, L., Lattanzi, R. (2011). Neuropeptides. In: F. Clementi & G. Fumagalli, General and Molecular Pharmacology. UTET, Turin

Publishing and Editorial Activity
• Guest Editor, Special Issue: GPCR: Roles in Cell Development and Disease, International Journal of Molecular Sciences, 2023
• Guest Editor, Special Issue: G Protein-Coupled Receptors: Molecular Mechanisms Involved in Receptor Activation and Selectivity, Life, 2023
• Guest Editor, Special Issue: Adipokines as Peripheral Signals for the Integration of Energy Balance and Reproduction, International Journal of Molecular Sciences, 2023
• Ad hoc reviewer for multiple international pharmacology journals

Publications Full-Length Publications
1) Amodeo G., Galimberti G., Lattanzi R. Brin A.T.M., Onnis V., Sacerdote P., Franchi S. (2025). Sexual dimorphism in vincristine-induced neuropathic pain, effect of prokineticin antagonism. Biomedicine & Pharmacotherapy 192:118596. I.F.=7.5
2) Vincenzi M., Kremic A., Tscheiller N., Hsu P., Chan MWY., Lattani R., Nebigil CG. (2025). Identification of prokineticin-2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids Br. J. Pharmacol., DOI: 10.1111/bph.70204 I.F.=7.7
3) Maftei D., Di Certo M.G., Maurizi R., Veltri F., Rosina M., Bissacco J., Mascioli D., Bovenzi R., Simonetta C., Mancini M., Buttarazzi V., Viola S., Gravina A., Maglie M.G., Rinaldi A.M., Gabanella F., Saso L., Stefani A., Passali F.M., Di Girolamo S., Pierantozzi M., Valle C., Ferri A., Mercuri N.B., Lattanzi R., Severini C., Schirinzi T. (2025). α-Synuclein-Related Mitochondria-Nrf2 Dysfunction in Parkinson's Disease Olfactory Mucosa. Ann Neurol. 12. doi: 10.1002/ana.27292.
4) Miele R., Fullone M.R., Casella I., Maftei D., Prosperi G., Manduca A., Lattanzi R.* (2025). Physical TRPV1-PKR2 interaction modulates PKR2 localization, activation and β-arrestin-2 recruitment. Cellular Signalling, 131: 111761. I.F.=3.7. *Corresponding author
5) D'Ottavio G., PezzaS., ModoniJ., Reverte I., Marchetti C., Zenoni S.F., De Pirro S., Maftei D., Lattanzi R., Esposito G., Ragozzino D., Merlo E., Venniro M., Ciccocioppo R., Fumagalli F., Milella M.S., Badiani A., Boix F., Caprioli D. (2025). Behavioural and pharmacokinetic analysis of heroin and cocaine self-administration: Effects of timeout on self-administration and choice in male rats. Br. J Pharmacol., 1–18. I.F.=7.7
6) Schirinzi T., Maftei D., Maurizi R., Albanese M., Simonetta C., Bovenzi R, Bissacco J.,
Mascioli D., Boffa L., Di Certo MG, Gabanella F., Francavilla B, Di Girolamo S., Mercuri NB, Passali FM, Lattanzi R.*, SeveriniC. ( 2 0 2 4 ) . Post‐COVID‐19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway. Molecular Neurobiology, I.F.=4.3. Co-last author.
7) Lattanzi R., Fullone M.R., De Biase A., Maftei D., Vincenzi M., Miele R. (2024). Biochemical characterization of Prokineticin 2 binding to Prokineticin receptor 1 in zebrafish. Neuropeptides, 107. I.F.=2.7
8) Lattanzi R. and Miele R. (2024). Genetic Polymorphisms of Prokineticins and Prokineticin Receptors Associated with Human Disease. Life, 14:1254. I.F. = 3.62
9) Lattanzi R., Casella I., Fullone M.R., Maftei D., Vincenzi M. and Miele R. ( 2 0 2 4 ) . Mapping the interaction site for β-arrestin-2 in the prokineticin 2 receptor. Cellular Signalling,119: 111175. I.F.=3.7
10)LattanziR.,CasellaI.,FulloneM.R.,MafteiD.,VincenziM.andMieleR.(2024). MRAP2 Inhibits β-Arrestin-2 Recruitment to the Prokineticin Receptor 2. Current Issues in Molecular Biology (CIMB) 46: 1607– 1620. I.F.= 3.0
11) Fullone M.R., Maftei D., Vncenzi M., Lattanzi R.*, Miele R. (2024). MRAP2a Binds and Modulates Activity and Localisation of Prokineticin Receptor 1 in Zebrafish. Int.J.Mol.Sci. 25, 7816. I.F.=4.9.ide *Co-corresponding author.
12) Gabanella F., Maftei D., Colizza A., Rullo E., Riminucci M., Pasqualucci E, Di Certo M.G., Lattanzi R., Possenti R., Corsi A., Greco A., De Vincentis M., Severini C. and Ralli M. (2024). Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma. ONCOLOGY LETTERS, 27: 37. I.F. = 3.11
13) Lattanzi R, Miele R. Interaction of Prokineticin Receptors with Accessory Proteins. Encyclopedia. 2023; 3(4):1498-1508. https://doi.org/10.3390/encyclopedia3040107
14) Vincenzi V., Kremic A., Jouve A., Lattanzi R., Miele R., Benharouga M., Alfaidy N., Migrenne- Li S., Kanthasamy A.G., Porcionatto M., Tetko I.V., Ferrara N., Désaubry L., Nebigil C.G. (2023). Therapeutic potential of targeting prokineticin receptors in diseases. Pharmacological Review, 1167-1199 I.F. = 20.479
15) Schirinzi T., Maftei D., Grillo P., Bovenzi R., Bissacco J., Simonetta C., Mascioli D., Zenuni H., Cerroni R., Vincenzi M., Maurizi R., Passali F.M., Di Girolamo S., Ralli M., Magliulo G., Tirassa P., Stefani A., Mercuri N.B., Lattanzi R.*, Severini C. (2023). Olfactory neuron substance P is overexpressed in Parkinson’s disease reflecting gut dysfunction. Movement Disorders. I.F.= 7.3. Co-last author.
16) Impellizzeri D., Maftei D., Severini C., Miele R., Balboni G., Siracusa R., Cordaro M., Di Paola R., Cuzzocrea S., Lattanzi R. *(2023). Blocking prokineticin receptors attenuates synovitis and joint destruction in collagen-induced arthritis. Journal of Molecular Medicine 101(5):569-580. I.F.= 5.2.*Corresponding author
17) Schirinzi T., Lattanzi R.*, Maftei D., Grillo P., Zenuni Hi., Boffa L., (2023). Substance P and Prokineticin 2 are overexpresed in olfactory nurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction. Brain, Behavior, and Immunity, 108: 302–308. I.F.= 19.27.* Co-first author.
18) Schirinzi T., Maftei D., Passali F.M., Grillo P., Zenuni H., Mascioli D, Maurizi R., Loccisano L., Vincenzi M., Rinaldi A.M., Ralli M., Di Girolamo S., Stefani A., Lattanzi R., Severini C., Mercuri N.B. (2022). Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson’s Disease. ANN. NEUROL.,00:1–9. I.F.= 11.2
19) Tucci P., Lattanzi R., Severini C., Saso L. (2022). Nrf2 pathway in Huntington’s disease (HD):which is the role? International Journal of Molecular Sciences (IJMS). I.F.= 6.208
20) Lattanzi R. and Miele R. (2022). Non-peptide agonists and antagonists of the prokineticin receptors. Current Issue in Molecular Biology (CIMB). I.F.= 3.139
21) Fullone M.R., Maftei D., Vincenzi M., Lattanzi R. and Miele R. ( 2 0 2 2 ) . Arginine 125 Is an Essential Residue for the Function of MRAP2. Int. J. Mol. Sci., 2: 17. I.F.= 6.01
22) Amodeo G, Maftei D, Lattanzi R, Verduci B, Comi L, Galimberti G, Sacerdote P, Franchi S. (2022). Controlling the activation of the prokineticin system as therapeutic approach to relief neuropathic pain and reduce neuroinflammation Pharmadvances, 4: 104-120.
23) Lattanzi R, Severini C, Miele R. ( 2 0 2 2 ) . Prokineticin 2 in cancer-related inflammation. Cancer Letters, 546, 215838. I.F.= 9.4
24) Maftei D., Schirinzi T., Mercuri N.B., Lattanzi R., Severini C. (2022). Potential Clinical Role of Prokineticin 2 (PK2) in Neurodegenerative Diseases Current Neuropharmacol. I.F.= 5.3
25) Fullone M.R., Maftei D., Vincenzi M., Lattanzi R.*, Miele R. (2022). Identification of Regions
Involved in the Physical Interaction between Melanocortin Receptor Accessory Protein 2 and
Prokineticin Receptor 2. Biomolecules, 12(3):474. I.F.= 5.88. *Co-corresponding author
26) Mascio G., Notartomaso S., Martinello K., Liberatore F., Bucci D., Imbriglio T., Cannella M., Antenucci N., Scarselli P., Lattanzi R., Bruno V., Nicoletti F., Fucile S., and Battaglia G. (2022). A progressive build-up of perineuronal nets in the somatosensory cortex is associated with the development of chronic pain in mice. Journal of Neuroscience, 22:1714-2i. I.F.= 6.167
27) Lattanzi R., Maftei D., Vincenzi M., Fullone MR., Miele R. (2022). Identification and Characterization of a New Splicing Variant of Prokineticin 2. Life, 12, 248. I.F.= 3.07
28) Lattanzi R., Miele R. ( 2 0 2 2 ) . Prokineticin-Receptor Network: Mechanisms of Regulation. Life, 12:172. I.F.= 3.78
29) Lucarini E., Seguella L., Vincenzi M., Parisio C., Micheli L., Toti A., Corpetti C., Del Re A., Squillace S., Maftei D., Lattanzi R., Ghelardini C., Di Cesare Mannelli L., Esposito G. (2021). Role of enteric glia as bridging element between gut inflammation and visceral pain consolidation during acute colitis in rats. Biomedicines, (2021), 9: 1671. I.F.= 6.1
30) Seguella L., Pesce M., Capuano R., Casano F., Pesce M., Corpetti C., Vincenzi M., Maftei D., Lattanzi R., Del Re A., Sarnelli G., Gulbransen B.D. and Esposito G. (2021). High-fat diet impairs duodenal barrier function and elicits glia-dependent changes along the gut-brain axis that are required for anxiogenic and depressive-like behaviors. Journal of Neuroinflammation, 18:115. I.F.= 6.829
31) Lattanzi R., Miele R. (2021). Versatile role of Prokineticins and Prokineticin Receptors in Neuroinflammation Biomedicines, 9: 1648. I.F.= 6.1
32) Schirinzi T., Maftei D., Ralli M., Greco A., Mercuri N.B., Lattanzi R., Severini C. (2021). Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment. Movement Disorder. I.F.= 9.698
33) Maftei D., Lattanzi R.*, Vincenzi M., Squillace S., Fullone M.R., Miele R. (2021). The balance of concentration between Prokineticin 2β and Prokineticin 2 modulates the food intake by STAT3 signaling. BBA Advances, 2021,1. I.F.= 3.7. *Corresponding author
34) Fiore M., Tarani L., Radicioni A., Spaziani M., Putotto C., Gabanella F., Maftei D., Lattanzi R., Minni A., Tarani F., Ferraguti G, Greco A, Petrella C. (2021). Serum Prokineticin-2 in Prepubertal and Adult Klinefelter Individuals. Canadian Journal of Physiology and Pharmacology (2021). I.F.= 1.946
35) Esposito G., Corpetti C., Pesce M., Seguella L., Annunziata G., Del Re A., Vincenzi M., Lattanzi R., Lu J, Sanseverino W. and Sarnelli A. (2021). Palmitoylethanolamide Producing Lactobacillus paracasei Improves Clostridium difficile Toxin A-Induced Colitis. Frontiers in Pharmacology I.F.= 5.988
36) Lattanzi R.*, Severini C., Maftei D., Saso L. and Badiani A. ( 2 0 2 1 ) . The Role of Prokineticin 2 in Oxidative Stress and in Neuropathological Processes. Frontiers in Pharmacology. I.F.= 5.988.*Corresponding author
37) Schirinzi T., Maftei D., Pieri M., Bernardini S., Mercuri NB., Lattanzi R., Severini C. ( 2 0 2 1 ) . Increase of Prokineticin- 2 in Serum of Patients with Parkinson's Disease. Movement Disorder. I.F.= 9.698
38) Fullone M.R., Lattanzi R., Maftei D., Bonaccorsi MC., Miele R. (2021). Analysis of role of aromatic residues in extracellular loop 2 of Prokineticin receptor 2 in ligand binding probed with genetically encoded photo- crosslinkers. Biochem. Biophys Acta Biomembr. I.F.= 1.507
39) Moschetti G., Kalpachidou T., Amodeo G., Lattanzi R., Sacerdote P., Kress M., Franchi S. (2020). Prokineticin Receptor Inhibition with PC1 protects Mouse Primary Sensory Neurons From Neurotoxic Effects of Chemotherapeutic Drugs in vitro. Frontiers in Immunology,11. I.F.= 7.561
40) Lattanzi R., Maftei D., Fullone M.R., Miele R. (2020). Trypanosoma cruzi trans-sialidase induces STAT3 and ERK activation by prokineticin receptor 2 binding. Cell Biochem. Funct. I.F.= 2.63
41) Maftei D., Vellani V., Artico M., Giacomoni C., Severini C., Lattanzi R. (2020). Abnormal Pain Sensation in Mice Lacking the Prokineticin Receptor PKR2: Interaction of PKR2 with Transient Receptor Potential TRPV1 and TRPA1. Neuroscience, 10; 427:16-28. I.F.= 3.056. *Corresponding author
42) Lattanzi R., Maftei D., Petrella C., Pieri M., Sancesario G., Schirinzi T., Bernardini S., Barbato C., Ralli M.., Greco A, Possenti R., Sancesario G., Severini C. (2019). Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimer's Disease: From Animal Models to the Human Pathology. Cells, 8 (11):1430. I.F.= 4.366
43) Maftei D., Ratano P., Fusco I., Marconi V., Squillace S., Negri L., Severini C., Balboni G., Steardo L., Bronzuoli M.R, Scuderi C., Campolongo P., Lattanzi R.* (2019). The prokineticin receptor antagonist PC1 rescues memory impairment induced by β Amyloid administration through the modulation of prokineticin system. Neuropharmacol., 158. I.F.= 4.431 *Corresponding author
44) Zuena A.R., Casolini P., Lattanzi R.*, Maftei D. Chemokines in Alzheimer’s Disease: New Insights into Prokineticins, Chemokine-Like Proteins. (2019). Front. Pharmacol.,10. I.F.= 4.225. *Corresponding author
45) Moschetti G., Amodeo G., Maftei D., Lattanzi R., Procacci P., Sartori P., Balboni G., Onnis V., Conte V., Panerai A., Sacerdote P., Franchi S. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib- induced peripheral neuropathy. (2019). J. Neuroinflamm.,16 (1):89. I.F.= 5.085.
46) Lattanzi R., Maftei D., Fullone M.R., Miele R. (2019). Identification and characterization of Prokineticin receptor 2 splicing variant and its modulation in an animal model of Alzheimer's disease. Neuropeptides, 73, 49–56. I.F.= 2.411
47) Zuena A.R., Maftei D., Alemà G.S., Dal Moro F., Lattanzi R., Casolini P. and Nicoletti F. (2018). Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol. Pain, 14: 1–9. I.F.= 4.225
48) Lattanzi R., Rief S., Schmidhammer H., Negri L. and Spetea M. (2018). In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist with Reduced Constipation in Mice. Front. Pharmacol., 9: 1-10. I.F.= 3.845
49) Lattanzi R., Maftei D., Negri L., Fusco I., Miele R. (2018). PK2β ligand, a splice variant of prokineticin 2, is able to modulate and drive signaling through PKR1 receptor. Neuropeptides, 71:32-42. I.F.= 2.407
50) Sarnelli G., Seguella L., Pesce M., L Jie., Gigli S., Bruzzese E., Lattanzi R., D’Alessandro A., Cuomo R., Steardo L. and. Esposito G. (2018). HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. J. Neuroinflamm., 15:94. I.F.= 5.7
51) Zinni M., Zuena A.R., Marconi V., Petrella C., Fusco I., Giuli C., Canu N., Severini C., Broccardo M., Theodorou V., Lattanzi R., Casolini P (2017). Maternal exposure to low levels of corticosterone during lactation protects adult rat progeny against TNBS-induced colitis: A study on GR-mediated anti-inflammatory effect and prokineticin system. PLoS One, 7;12(3). I.F.= 2.766
52) Caioli S., Severini C., Ciotti T., Florenzano F., Pimpinella D., Petrocchi Passeri P., Balboni G., Polisca P., Lattanzi R., Nisticò R., Negri L., Zona C. (2017). Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease. Neuropharmacol., 116, 82-97. I.F.= 4.249
53) Taurone S., Ripandelli G., Minni A., Lattanzi R., Miglietta S., Pepe N., Fumagalli L., Micera A., Pastore F.S. and Artico M. (2016). Age-related ultrastructural and monoamine oxidase changes in the rat optic nerve. JBRHA, 30, 903-908. I.F.= 1.406
54) Landucci E., Lattanzi R., Gerace. E, Scartabelli T., Balboni G., Negri L., Pellegrini-Giampietro D.E. (2016). Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. Neuropharmacol., 108, 39-48. I.F.= 5.012
55) Hoffmann T., Negri L., Maftei D., Lattanzi R., Reeh P.W. The prokineticin Bv8 sensitizes cutaneous terminals of female mice to heat. (2016). Eur. J. Pain, 20 (8): 1326-34. I.F.= 3.09
56) Castelli M., Amodeo G., Negri L., Lattanzi R., Maftei D., Gotti C., Pistillo F., Onnis V., Congu
C., Panerai A.E., Sacerdote., Franchi S. (2016). Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes. PLoS One, 5;11(1).
I.F.= 2.806
57) Severini C., Lattanzi R.*, Maftei D., Marconi V., Ciotti M.T., Petrocchi Passeri P., Florenzano
F., Del Duca E., Caioli S., Zona C., Balboni G., Salvadori S., Nisticò R., Negri L. (2015). Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity. Sci. Rep., 19, 5. I.F.= 5.228. * Co- first author
58) Guida F., Luongo L., Marmo F., Romano R., Iannotta M., Napolitano F., Belardo C., Marabese I., D'Aniello A., De Gregorio D., Rossi. F, Piscitelli F., Lattanzi R., de Bartolomeis A., Usiello A., Di Marzo V., de Novellis V., Maione S. (2015). Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol. Brain., 12;8:47. I.F.= 3.745
59) Truini A., Piroso S., Pasquale E., Notartomaso S., Di Stefano G., Lattanzi R., Battaglia G., Nicoletti F., Cruccu G. (2015). N-acetyl-cysteine, a drug that enhances the endogenous activation of group-II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. Mol. Pain, 11, 14. I.F.= 3.07
60) Abou-hamdan M., Costanza M., Fontana E., Di Dario M., Musio S., Congiu C., Onnis V., Lattanzi R., Radaelli M., Martinelli V., Salvadori S., Negri L., Poliani P.L., Farina C., Balboni G., Steinman L., and Pedotti R. (2015). Critical role for prokineticin 2 in central nervous system autoimmunity. Neurol. Neuroimmunol. Neuroinflamm. MS ID#: NEURIMMINFL/2014/003723. I.F. not available for the year 2015.
61) Lattanzi R., Maftei D., Marconi V., Florenzano F., Franchi S., Borsani E., Fabrizio Rodella L., Balboni G., Salvadori S., Sacerdote P. and Negri L. (2015). Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model. BioMed Res. Int. Hindawi, I.F.=2.134
62) Guida F., Lattanzi R.*, Boccella S., Maftei D., Romano R., Marconi V., Balboni G., Salvadori S., Scafuro MA., De Novellis V., Negri L., Maione S., Luongo L. (2015). PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice. Pharmacol. Res., 91, 36-46. I.F.=4.816 * Co-first author
63) Lattanzi R., Congiu C., Onnis V., Deplano A., Salvadori S., Marconi V., Maftei D., Francioso A., Ambrosio C., Casella I., Costa T., Caltabiano G., Matsoukas MT., Balboni G., Negri L. (2014). Halogenated triazinediones behave as antagonists of PKR1: in-vitro and in-vivo pharmacological characterization. IJPSR, 5 (11), 5066-5074. I.F.=0.43
64) Congiu C., Onnis V., Deplano A., Salvadori. S, Marconi V., Maftei D., Negri L., Lattanzi R. and Balboni G. (2014). A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists. Eur. J. Med. Chem.,81:334-40. I.F.=3.477
65) Maftei D., Marconi V., Florenzano F., Giancotti L.A., Castelli M., Moretti S., Borsani E., Rodella LF., Balboni G., Luongo L., Maione S., Sacerdote P., Negri L., Lattanzi R. (2014). Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals Br. J. Pharmacol., 171, 4850– 4865. I.F.=4.84
66) Beale K.E.L., Gardiner J.V., Bewick G.A., Hostomska K, Patel N.A., Hussain S.S., Jayasena C.N., Ebling F.J., Jethwa P.H., Prosser H.M., Lattanzi R, Negri L, Ghatei M.A., Bloom S.R., Dhillo W.S. (2013). Peripheral administration of prokineticin 2 potently reduces food intake and body weight in mice via the brainstem. Br. J. Pharmacol., 168(2), 403-10. I.F.=4.99
67) Negri L. and Lattanzi R. (2012). Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr. Opin. Pharmacol., 12, 62-66. I.F.=5.443
68) Lattanzi R., Sacerdote P., Franchi S., Canestrelli M., Miele R., Barra D., Visentin S., De Nuccio C., Porreca F., De Felice M., Guida F., Luongo L., De Novellis V., Maione S. and Negri L. (2012). Pharmacological activity of a Bv8 analog modified in position 24. Br. J. Pharmacol., 166, 950-963. I.F.=5.067
69) Negri L., Lattanzi R. (2011). Bv8-Prokinetins and Their Receptors: Modulators of Pain. Curr. Pharm. Biotechnol. 12, 1720-1727. I.F.=2.805
70) Jacobson O., D. Weiss I., Niu G., Li W., Balboni G., Congiu C., Onnis V., Kiesewetter D.O., Lattanzi R., Salvadori S., Chen X. (2011). Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain. Journal of Nuclear Medicine, 52 (4), 602-607.
I.F.=6.381
71) Miele R., Lattanzi R., Bonaccorsi Di Patti M.C., Paiardini A., Negri L., Barra D. (2010).
Expression of Bv8 in Pichia Pastoris to identify structural features for receptor binding. Protein
Expression and Purification, 73 (1), 10-4. I.F.=1.644
72) Galeazzi R., Martelli G., Marcucci E., Orena M., Rinaldi S., Lattanzi R., Negri L. (2010).
Analogues of both Leu- and Met-enkephalin containing a costrained dipeptide isostere prepared
from Basylis-Hillman adduct. Amino Acid, 38 (4), 14646-14651. I.F.=4.106
73) Negri L., Lattanzi R., Giannini E., Canestrelli M., Nicotra A., Melchiorri P. (2009). Bv8/Prokineticins and their receptors: a new pronociceptive system. International Review of
Neurobiology, 85, 145-157. I.F.=4.017
74) Giannini E., Lattanzi R., Nicotra A., Campese A.F., Grazioli P., Screpanti I., Balboni G., Severo
S., Sacerdote P., Negri, L. (2009). The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. PNAS, 106 (34), 14646-14651. I.F.=9.432
75) Ballett S., Feytens D., De Wachter R., De Vlaeminck M., Markzac E.D., Salvadori, S., De Graaf C., Rognan D., Negri L., Lattanzi R., Lazarus L.H., Tourwed D., Balboni, G. (2009). Conformationally constrained opioid ligands: The Dmt-Aba- and Dmt-Aia versus Dmt-Tic scaffold. Bioorganic & Medicinal Chemistry Letters, 19, 433-437. I.F.=2.65
76) Balboni G., Lazzari I., Trapella C., Negri L., Lattanzi R., Giannini E., Nicotra A., Melchiorri P., Visentin S., De Nuccio C., and Salvadori S. (2008). Triazine Compounds as Antagonists at Bv8-Prokineticin Receptors. J. Med. Chem., 51, 7635-7639. I.F.=4.898
77) Franchi S., Giannini E., Lattuada D., Lattanzi R., Melchiorri P., Negri L., Sacerdote P. (2008). The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunology, 9, 60. I.F.=2.661
78) Salvadori S., Trapella C., Fiorini S., Negri L., Lattanzi R., Bryant S.D., Jinsmaa Y., Lazarus L.H., Balboni G. (2007). A new opioid designed multiple ligand derived from the mu opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorganic & Medicinal Chemistry, 15, 6876-6881. I.F.=2.662
79) De Novellis V., Negri L., Lattanzi R., Rossi F., Palazzo E., Marabese I., Giannini E., Vita D., Melchiorri P., Maione S. (2007). The prokineticin receptor agonist Bv8 increases GABA release in the periaqueductal grey and modifies RVM cell activities and thermoceptive reflexes in the rat. European Journal of Neuroscience., 26 (2), 3068-3078. I.F.=3.673
80) Negri L., Lattanzi R., Giannini E., Melchiorri P. (2007). Bv8/Prokineticin proteins and their Receptors. Life Science, 81, 1103-1116. I.F.=2.257
81) Biondi L., Filira F., Giannini E., Gobbo M., Lattanzi R., Negri L., Rocchi R. (2007). Novel glycosylated [Lys7]dermorphin analogues: synthesis, biological activity and conformational investigations. J. Pept. Sci., 13 (3), 179-189. I.F.=1.768
82) Vellani V., Colucci M., Lattanzi R., Giannini E., Negri L., Melchiorri P., Mcnaughton. P. (2006). Sensitization of Transient Receptor Potential Vanilloid 1 by the Prokineticin Receptor Agonist Bv8. The Journal of Neuroscience, 26(19), 5109-5116. I.F.=7.453
83) Vazquez M.E., Blanco J.B., Salvadori S., Trapella C., Argazzi R., Bryant S.D., Jinsmaa Y., Lazarus L.H., Negri L., Giannini E., Lattanzi R., Colucci M., Balboni G. (2006). 6-N,N- Dimethylamino-2,3-naphthalimide: A New Environment-Sensitive Fluorescent Probe in δ- and μ-Selective Opioid Peptides. J. Med. Chem., 49, 3653-3658. I.F.=5.115
84) Pontieri F.E., Lattanzi R., Benincasa D., Cavallari M., Negri L., Orzi, F. (2006). Effects of the intravenous administration of [Lys7]dermorphin on local cerebral glucose utilization in the rat. Eur. J. Pharmacol., 544 (1-3), 17-20. I.F.=2.522
85) Negri L., Lattanzi R., Giannini E., Melchiorri P. (2006). Modulators of Pain: Bv8 and Prokineticins. Current Neuropharmacology, 4, 207-215. I.F.=0.981
86) Negri L., Lattanzi R., Giannini E., Colucci M., Margheriti F., Melchiorri P., Vellani V., Tian H., De Felice M. & Porreka, F. (2006). Impaired Nociception and Inflammatory Pain Sensation in Mice Lacking the Prokineticin Receptor PKR1: Focus on Interaction between PKR1 and the Capsaicin Receptor TRPV1 in Pain Behaviour. The Journal of Neuroscience, 26 (25), 6716- 6727. I.F.=7.453
87) Biondi B., Goldin D., Giannini E., Lattanzi R., Negri L., Melchiorri P., Ciocca L., Rocchi R. (2006). Novel Nociceptin Analogues: Synthesis and Biological Activity. International Journal of Peptide Research and Therapeutics, 12 (2), 139-144. I.F.=0.536
88) Biondi B., Giannini E., Negri L., Melchiorri P., Lattanzi R., Rosso F., Ciocca L., Rocchi R. (2006). Opioid Peptides: Synthesis and Biological Activity of New Endomorphin Analogues. International Journal of Peptide Research and Therapeutics, 12 (2), 145-151. I.F.=0.536
89) Ballet S., Salvadori S., Trapella C., Bryant S.D., Jinsmaa Y., Lazarus L.H., Negri L., Giannini E., Lattanzi R., Tourwe’ D., Balboni G. (2006). New 2’, 6’- Dimethyl-L-tyrosine (Dmt) Opioid Peptidomimetics Based on the Aba-Gly Scaffold. Development of Unique μ-Opioid Receptor Ligands. J. Med. Chem., 49, 3990-3993. I.F.=5.115
90) Negri L., Lattanzi R., Giannini E., Colucci M., Grohovaz F., Codazzi F., Mignogna G., Barra D., Kaiser A., Kreil G., Melchiorri, P. (2005). Biological activity of Bv8 analogues. Br. J. Pharmacol., 146, 625-632. I.F.=3.41
91) Lattanzi R., Spetea M., Schullner F., Rief S.B., Krassing R., Negri L., Schmidhammer H. (2005). Synthesis and Biological Evaluation of 14-Alkoxymorphinians.22. 1 Influence of the 14-Alkoxy Group and the Substitution in Position 5 in 14-14-Alkoxymorphinian-es in Vitro and in Vivo Activities. J. Med. Chem., 48, 3372-3379. I.F.=4.926
92) Balboni G., Salvadori S., Dal Piaz A., Bortolotti F., Argazzi R., Negri L., Lattanzi R., Bryant S.D., Jinsmaa Y., Lazarus L.H. (2004). Highly Selective Fluorescent Analogue of the potent δ - Opioid Receptor Antagonist Dmt-Tic. J. Med. Chem., 47, 6541-6546. I.F.=5.076
93) Negri L., Lattanzi R., Giannini E., De Felice M., Colucci A., Melchiorri P. (2004). Bv8, the amphibian homologue of the mammalian prokineticins, modulates ingestive behaviour in rats. Br. J. Pharmacol, 142, 181-191. I.F.=3.32
94) Negri L., Lattanzi R., Giannini E., Metere A., Colucci M.A., Barra D., Kreil, G., Melchiorri P. (2002). Nociceptive sensitization by the secretory protein Bv8. Br. J. Pharmacol., 137, 1147- 1154. I.F.=3.45
95) Lattanzi R., Negri L., Schmidhammer H., Giannini E. (2002). Antinociceptive activity of a novel buprenorphine analogue. Life Sciences, 70, 2177-2185. I.F.=1.824
96) Lattanzi R., Negri L., Giannini E., Schmidhammer H., Schutz J., Improta G. (2001). HS-599: a novel long acting opioid analgesic does not induce place-preference in rats. Br. J. Pharmacol.,134, 441-447. I.F.=3.5
97) Slowe S.J., Clarke S., Lena I., Goody R.J., Lattanzi R., Negri L., Simonin F., Matthes H.W.D., Filliol D., Kieffer B.L., Kitchen I. (2001). Autoradiographic mapping of the opioid receptor-like 1 (ORL1) receptor in the brains of the μ-, δ-, OR-, κ-opioid receptor knockout mice. Neuroscience, 106, (3), 469-480. I.F.=3.219
98) Schutz J., Krassnig R., Schmidhammer H., Wurst K., Lattanzi R., Negri L. (2001). Synthesis and pharmacological evaluation of 18,19-Dehydrobuprenorphine. Heterocycles, 54, (2), 989- 998. I.F.=0.970
99) Negri L., Melchiorri P., Lattanzi R. (2000). Pharmacology of Amphibian Opiate Peptides. Peptides, 21, 1639-1647. I.F.=1.867
100) Negri L., Broccardo M., Lattanzi R., Melchiorri P. (1999). Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats. Br. J. Pharmacol., 128, 1554-1560. I.F.=3.72
101) Negri L., Lattanzi R., Borsodi A. Toth G., Salvadori S. (1999). Differential knockdown of δ -opioidreceptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA. Antisense &Nucleic Acid Drug Development, 9, 203-211. I.F.=3.441
102) Negri L., Lattanzi R., Tabacco F., Orru’ L., Severini C., Scolaro B., Rocchi R. (1999). Dermorphin and delthorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration. J. Med. Chem., 42, (3), 400-404. I.F.=4.079
103) Negri L., Lattanzi R., Tabacco F., Scolaro B., Rocchi R. (1998). Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br. J. Pharmacol., 124, 1516-1522. I.F.=3.7
104) Negri L., Lattanzi R., Tabacco F. & Melchiorri P. (1998). Respiratory and cardiovascular effects of the μ-opioid receptor agonist [Lys7] dermorphin in awake rats. Br. J. Pharmacol., 124, 345-355. I.F.=3.7
105) Negri L., Severini C., Lattanzi R., Potenza R.L. & Melchiorri P. (1997). Postnatal development of d-opioid receptor subtypes in mice. Br. J. Pharmacol., 120, 989-994. I.F.=3.6
106) Negri L., Improta G., Lattanzi R., Potenza R.L., Luchetti F. & Melchiorri P. (1995). Interaction between the μ-agonist dermorphin and the δ -agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and δ -opioid receptor binding. Br. J. Pharmacol., 116, 2931-2938. ((I.F. not available because the year 1995 is not included in the Journal Citation Report)"
107) Negri L., Lattanzi R. & Melchiorri P. (1995). Production of antinociception by peripheral administration of [Lys7]dermorphin, a naturally occurring peptide with high affinity for μ- opioid receptors. Br. J. Pharmacol., 114, 57-66. (I.F. not available because the year 1995 is not included in the Journal Citation Report)"

Rome, October 2025
Roberta Lattanzi